The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing

被引：21
|
作者：
Ye, Lingqun [1 ,2 ]
Ni, Xuan [1 ,2 ]
Zhao, Zhen-Ao [1 ,2 ,3 ,4 ]
Lei, Wei [1 ,2 ,3 ,4 ]
Hu, Shijun [1 ,2 ,3 ,4 ]
机构：
[1] Soochow Univ, Coll Med, Affiliated Hosp 1, Inst Cardiovasc Sci, Suzhou 215000, Peoples R China
[2] Soochow Univ, Coll Med, Affiliated Hosp 1, Dept Cardiovasc Surg, Suzhou 215000, Peoples R China
[3] Key Lab Stem Cells & Biomed Mat Jiangsu Prov, Suzhou 215000, Peoples R China
[4] Chinese Minist Sci & Technol, Suzhou 215000, Peoples R China
来源：
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH | 2018年 / 11卷 / 05期
基金：
中国国家自然科学基金; 国家重点研发计划;
关键词：
Induced pluripotent stem cells; Cardiovascular diseases; Disease modeling; Drug testing; LONG-QT SYNDROME; IPSC-DERIVED CARDIOMYOCYTES; HYPERTROPHIC CARDIOMYOPATHY; DILATED CARDIOMYOPATHY; TISSUE; PHENOTYPE; HEART; RECAPITULATE; GENERATION; MATURATION;
D O I：
10.1007/s12265-018-9811-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In recent decades, cardiovascular diseases have become the greatest health threat to human beings, and thus it is particularly important to explore the subtle underlying pathogenesis of cardiovascular diseases. Although many molecular pathways have been explored to be essential in the development of cardiovascular diseases, their clinical significances are still uncertain. With the emergence of induced pluripotent stem cells (iPSCs), a unique platform for cardiovascular diseases has been established to model cardiovascular diseases on specific genetic background in vitro. This review summarizes current progresses of iPSCs in cardiovascular disease modeling and drug testing. This review highlighted iPSC-based cardiovascular disease modeling and drug testing. The technical advances in iPSC-based researches and various clinically relevant applications are discussed. With further intensive research, iPSC technology will shape the future of clinical translational research in cardiovascular diseases.
引用
收藏
页码：366 / 374
页数：9
相关论文
共 50 条
  • [21] Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery
    Jong, Jiho
    Yoo, Jeong-Eun
    Lee, Jeong-Ah
    Lee, Dongjin R.
    Kim, Ji Young
    Huh, Yong Jun
    Kim, Dae-Sung
    Park, Chul-Yong
    Hwang, Dong-Youn
    Kim, Han-Soo
    Kang, Hoon-Chul
    Kim, Dong-Wook
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2012, 44 (03): : 202 - 213
  • [22] Induced pluripotent stem cells in disease modelling and drug discovery
    Rowe, R. Grant
    Daley, George Q.
    NATURE REVIEWS GENETICS, 2019, 20 (07) : 377 - 388
  • [23] Induced pluripotent stem cells in disease modelling and drug discovery
    R. Grant Rowe
    George Q. Daley
    Nature Reviews Genetics, 2019, 20 : 377 - 388
  • [24] The Future of Induced Pluripotent Stem Cells for Cardiac Therapy and Drug Development
    Thorrez, Lieven
    Sampaolesi, Maurilio
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (30) : 3258 - 3270
  • [25] Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells
    Xiao-hong Xu
    Zhong Zhong
    Acta Pharmacologica Sinica, 2013, 34 : 755 - 764
  • [26] Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform-A Cardiac Perspective
    Bekhite, Mohamed M.
    Schulze, P. Christian
    CELLS, 2021, 10 (12)
  • [27] Modeling Huntington's disease with induced pluripotent stem cells
    Kaye, Julia A.
    Finkbeiner, Steven
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2013, 56 : 50 - 64
  • [28] Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells
    Xu, Xiao-hong
    Zhong, Zhong
    ACTA PHARMACOLOGICA SINICA, 2013, 34 (06) : 755 - 764
  • [29] Induced pluripotent stem cells and hematological malignancies: A powerful tool for disease modeling and drug development
    Donada, A.
    Basso-Valentina, F.
    Arkoun, B.
    Monte-Mor, B.
    Plo, I
    Raslova, H.
    STEM CELL RESEARCH, 2020, 49
  • [30] Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation
    Fotios Sampaziotis
    Miguel Cardoso de Brito
    Pedro Madrigal
    Alessandro Bertero
    Kourosh Saeb-Parsy
    Filipa A C Soares
    Elisabeth Schrumpf
    Espen Melum
    Tom H Karlsen
    J Andrew Bradley
    William T H Gelson
    Susan Davies
    Alastair Baker
    Arthur Kaser
    Graeme J Alexander
    Nicholas R F Hannan
    Ludovic Vallier
    Nature Biotechnology, 2015, 33 : 845 - 852
12345